The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to provide a retatrutide half life significant substantial decrease in body weight and benef